AtaiBeckley's BPL-003 could redefine psychedelics dosing, Jefferies analysts believe

Impact · against what's priced in

ATAI is positioned as a high-upside play following differentiated Phase 2b data for BPL-003, which suggests a more efficient dosing schedule than competitors. The clear regulatory timeline for Phase 3 and the Jefferies 'Buy' rating provide concrete catalysts for valuation expansion.

ATAI+0.70: No priced-in read yet
In context: Phase 2b results showing a 63% response rate and 48% remission for BPL-003, combined with single-dose durability that may only require re-dosing every 2-3 months, differentiate the asset from existing TRD treatments.
Read from the article alone

AtaiBeckley's BPL-003 could redefine psychedelics dosing, Jefferies analysts believe

biotech
healthcare
ATAI
analyst rating
clinical trials
depression
fda
pharma
phase 2
phase 3
psychedelics

AtaiBeckley's BPL-003 could redefine psychedelics dosing, Jefferies analysts believe

What matters in this story

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

AtaiBeckley's BPL-003 could redefine psychedelics dosing, Jefferies analysts believe

What matters in this story

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

How each ticker is affected

Connected tickers

Track these names every morning.

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

2 healthcare stocks to turn $10 into $100 by next year

TransMedics: 2027 Setting Up To Be A Pivotal Year

AtaiBeckley's BPL-003 could redefine psychedelics dosing, Jefferies analysts believe

What matters in this story

Next reads from the same story arc

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

AtaiBeckley's BPL-003 could redefine psychedelics dosing, Jefferies analysts believe

What matters in this story

Next reads from the same story arc

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

How each ticker is affected

Connected tickers

Track these names every morning.

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

2 healthcare stocks to turn $10 into $100 by next year

TransMedics: 2027 Setting Up To Be A Pivotal Year